



NDA 19384/S-063

SUPPLEMENT APPROVAL

Merck Sharp and Dohme Corporation
Attention: Kristin Rittenhouse
Manager, Worldwide Regulatory Affairs
P.O. Box 1000, UG2C-50
North Wales, PA 19454-2505

Dear Ms. Rittenhouse:

Please refer to your Supplemental New Drug Application (sNDA) dated April 16, 2012, received April 16, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Noroxin (norfloxacin) 400 mg Tablets.

This “Prior Approval” supplemental new drug application revises the ADVERSE REACTIONS, Post-marketing sub-section of the product labeling to include the term DRESS (drug rash with eosinophilia and systemic symptoms) syndrome.

The supplement also provides for the addition of the sentence “Skin rash accompanied by fever and feeling unwell” to the Medication Guide, under the heading “What are the possible side effects of Noroxin?” subheading Serious allergic reactions.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your April 16, 2012, submission includes final printed labeling (FPL) for your package insert, and, Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm.D., Regulatory Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
06/15/2012